While amyloid/tau/neurodegeneration (ATN) imaging biomarker approaches enable us to identify AD pathology in early stages, determining aMCI in patients remains challenging, especially true when using MRI and limited clinical information, and when advanced amyloid/tau PET and extensive neuropsychiatric tests are not available. The gene discussed is MAPT; the disease is Alzheimer disease.